Physician profile
Michael E Merrick
NPI 1326048414
$388.58
in general payments reported to CMS, 2019-2025
9 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $188 · 2021: $60.72 · 2022: $140.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $105.19 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $84.14 | 2019-2021 | |
| Teva Pharmaceuticals USA, INC. | $69.73 | 2019 | |
| Allergan, INC. | $64.04 | 2019 | |
| Grifols USA, LLC | $19.67 | 2019 | |
| Pfizer INC. | $18.18 | 2022 | |
| Lilly USA, LLC | $16.75 | 2022 | |
| Sanofi-Aventis U.S. LLC | $10.88 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$125.00 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Merrick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.